https://www.selleckchem.com/pr....oducts/glumetinib.ht
Baseline factors associated with a higher rate of HBsAg loss were male sex, Caucasian race, genotype A, age ≥40 years, and cirrhosis. HBsAg loss rates did not differ significantly between those who received short-term (≤24 weeks) vs long-term (24 weeks) therapy. Both HBeAg and HBsAg loss were significantly associated with improved clinical outcomes. Early response (HBeAg loss) was associated with more HBsAg loss and better patient outcomes. During long-term follow-up, high rates of HBsAg loss were observed from a single (PEG)IFN-
Curtir
Comentario
Compartilhar
